P-糖蛋白与ER、PR在乳腺癌中的表达及意义

Expression and its singnificance of MDR, estrogen receptor and progesterone receptor in breast cancer

目的：探讨耐药基因P－糖蛋白（P－gP）在乳腺癌的表达，以及与组织学类型、淋巴结转移、ER和PR之间的相互关系，为乳腺癌的优化化疗，预测预后提供有用的指标的方法：应用免疫组化检测37例乳腺癌和10例非癌病变的P－gP、ER、PR。结果：ER、PR的阳性率分别为43．24％和40．54％，P－gP的表达率为70％，27例P－gP阳性病例中有50％左右ER和PR同时表达。结论：乳腺癌是耐药基因P－gP高表达肿瘤，P－gP与组织学类型、淋巴结转移之间无相互关系，与ER、PR有关，提示乳腺癌的化疗若辅于性激素治疗，疗效可能更好。

Puepose To reveal the correspondence between the expression of multidrug resistance(MDR) gene and estrogen receptor(ER)and progesterone receptor(PR) in breast cancer. Materials and Methods:The immunohistoche ndcal way LSAB was employed to estimated the MDR, expressed as P－glycoprotein(P－gP), ER and PR of surgically dissected tissue in 37 cases of breast cancer and 10 cases of benign breast disorders. Results: P－gP positive was obtained in 27 cases(70. 27% ) Er positive as in 16 cases(43. 24% ) and PR Positive was found in 15 cases(40. 54% ) of 37 breast cancers. Out of 27 P－gP POsitive cases, 13 (48. 15) were ER POsitive and 14 (51. 85% ) PR Positive. Conclusions: Breast cancer reveals high expression of GDR gene with a phenomenos of parallel to the expression of ER and PR simultaneously. The result of the study offers a positive evidence for the current strategy of the management of breast cancer, i. e., the combination of chemotherapy and endocrine therapy in most occasion.